---
figid: PMC7913382__jcm-10-00566-g004
figtitle: STAT3 activation via the JAK-STAT pathway (cytokine and growth factor receptor
  stimulation) and cytoplasmic Src kinase
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC7913382
filename: jcm-10-00566-g004.jpg
figlink: pmc/articles/PMC7913382/figure/jcm-10-00566-f004/
number: F4
caption: Overview of STAT3 activation via the JAK-STAT pathway (cytokine and growth
  factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor (ruxolitinib),
  STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor (dasatinib) are
  currently in clinical trials for pancreatic cancer.
papertitle: The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic
  Cancer Therapies.
reftext: Andres Garcia-Sampedro, et al. J Clin Med. 2021 Feb;10(4):566.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9570572
figid_alias: PMC7913382__F4
figtype: Figure
redirect_from: /figures/PMC7913382__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7913382__jcm-10-00566-g004.html
  '@type': Dataset
  description: Overview of STAT3 activation via the JAK-STAT pathway (cytokine and
    growth factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor
    (ruxolitinib), STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor
    (dasatinib) are currently in clinical trials for pancreatic cancer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ruxolitinib
  - tyrosine
  - Dasatinib
---
